Collaboration leads to discoveries that leads to cures
In over four decades, our collaborative research has made significant contributions to the field of cancer research and helped us all move closer to curing cancer. Below are some highlights of our collaborations and discoveries:
1978: Demonstrated that leukemia cells can be made to undergo differentiation and gain a normal function, which became the basis for differentiation therapy.
1980: Discovered that a folic acid derivative can improve the clinical efficacy of a chemotherapeutic agent in the treatment of colon cancer. This discovery is still used today to treat forms of colon cancer.
1982: The SWCRF launches its historic collaboration with the Shanghai Second Medical University and Shanghai Institute of Hematology just as the governments of the United States and China began normalizing relations.
1997: The SWCRF collaboration with the Shanghai Institute of Hematology leads to the clinical treatment of Acute promyelocytic leukemia (APL) that has a greater than 90% cure rate and is still in use today. The treatment combined Arsenic trioxide (ATO) with retinoic acid (RA).
2003: SWCRF-funded research with Ethan Dmitrovsky, M.D. and a lab at Dartmouth Medical School designed cancer-specific targets in lung cancer that resulted in a clinical trial.
2018: Dr. Waxman leads the formation of the Partnership for Aging and Cancer Research Program with the National Cancer Institute (NCI) and National Institute on Aging. This two-year collaboration will direct up to $3 million towards research that studies the links between aging and cancer.